Clinical Trials Logo

Clinical Trial Summary

This is an open-label, Phase I single dose 2-part, crossover bioequivalence study under fasted conditions. The trial is designed to evaluate the pharmacokinetic parameters between single doses of 100mg ensartinib capsules manufactured by two different processes.


Clinical Trial Description

A Phase I, randomized, open-label single dose, 2-part, crossover bioequivalence study under fasted conditions to compare 100 mg capsules manufactured using the proposed commercial manufacturing process to the corresponding capsules which were utilized in the Phase III clinical study manufactured by a different process. A total of 32 healthy subjects were divided evenly and were randomized into 1 of the 2 treatment sequences (T-R or R-T) prior to Period 1 dosing. Subjects received the test product (100 mg ensartinib hydrochloride capsules manufactured with the registration stability process) or the reference product (100 mg ensartinib hydrochloride capsules utilized in the Phase 3 trial) according to their assigned treatment sequence. The single dose crossover study will have a minimum washout period of 14 days. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05665283
Study type Interventional
Source Xcovery Holdings, Inc.
Contact
Status Completed
Phase Phase 1
Start date November 29, 2022
Completion date August 8, 2023

See also
  Status Clinical Trial Phase
Unknown status NCT01227811 - Single Dose Two-periods Crossover Bioequivalence Study of Darifenacin Tablets in Healthy Volunteers. Phase 1
Completed NCT00803946 - Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fed Conditions Phase 1
Completed NCT01039233 - Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex 50 mg Tablet in Healthy Subjects Under Fasting Conditions Phase 1
Completed NCT00804401 - Bioequivalence Study Between Two Oral Formulations of Naproxen 500 mg Tablets Under Fasting Conditions Phase 1
Completed NCT00803764 - Bioequivalence Study Between Two Oral Formulations of Naproxen 500 mg Tablets Under Fed Conditions Phase 1
Completed NCT00804440 - Bioequivalence Study Between Two Oral Formulations of Ibuprofen 800 mg Tablets Under Fasting Conditions Phase 1
Unknown status NCT01229280 - Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers. Phase 1